2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2902

Antibodies to PAD4 Drive Monocyte Activation and Differentiation into Osteoclast-like Cells
Abstract Number: 1108

Antibody Repertoire Dynamics in Systemic Sclerosis after Myeloablative Autologous Hematopoietic Stem-Cell Transplantation or Cyclophosphamide Treatment
Abstract Number: 114

Antifibrotic Regulation By Response Gene to Complement 32 Protein
Abstract Number: 852

Antigenic Property of Prothrombin/HLA-DR Complex on Procoagulant Cells in Patients with Antiphospholipid Syndrome
Abstract Number: 376

Antisynthetase Syndrome: Prevalence of Serositis in Autoantibody Subsets
Abstract Number: 1943

Apolipoprotein L1 Risk Variants Associate with Poor Renal Outcomes, Damage Accrual, and Death: A Prospective Ghanaian SLE Cohort
Abstract Number: 107

Apolipoprotein L1 Risk Variants, Renal Histopathology, and Prognosis in African American SLE Nephritis Patients: A Cohort Study
Abstract Number: 1691

Application of the Doris Algorithm for the Definition of Disease Remission and Its Relation with Damage Accrual over a 2-Year Period in a Cohort of Italian Patients with Systemic Lupus Erythematosus Classified According to Clinical Disease Patterns
Abstract Number: 1379

Appraisal of the Educational Needs in Patients with Osteoarthritis Using the Educational Needs Assessment Tool Questionnaire
Abstract Number: 2656

Apremilast As Treatment of Refractory Skin Lupus Lesions
Abstract Number: 2841

Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup
Abstract Number: 1772

Apremilast in Refractory Oral and/or Genital Ulcers in Behçet’s Disease. Multicenter Study of 37 Cases
Abstract Number: 143

Aquaporin 3 (AQP3) Protein Is Highly Expressed in Psoriatic Plaques and AQP3 Gene Expression Strongly Induced By IL-23 in CD4+ Th17 Cells
Abstract Number: 762

Aquaporin-4 Immunoglobulin G Antibody Positive Neuromyelitis Optica Spectrum Disorder and Systemic Autoimmune Diseases Overlap Syndrome: A Single Center Experience
Abstract Number: 1481

Are ACPA Associated with More Bone Loss over Time in Patients with RA?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].